The objectives of this contract are: 1) when testing new agents which have just completed Phase I trials, to confirm that the dose and schedule chosen can be safely given in subsequent Phase II trials; 2) to determine the antitumor activity of existing antitumor agents which can be administered in significantly higher doses when used with colony stimulating factors or other factors which modulate toxicity and antitumor activity; 3) to determine the antitumor activity of combinations of antitumor agents and modalities; 4) to evaluate the laboratory parameters which may correlate with or predict for response; and 5) to determine the spectrum of antitumor activity for new agents in selected human cancers. While the contract will permit occasional Phase III trials, the major emphasis shall be on the early Phase II studies which are pivotal for drug development and require rapid initiation, completion and data reporting.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM007309-005
Application #
3607916
Study Section
Project Start
1990-05-01
Project End
1996-11-30
Budget Start
1992-06-10
Budget End
1992-11-30
Support Year
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905